

COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT #3

Receipt

In re Application of
Jean-Rene Authelin, et. al.

Serial No.: 09/871,876

Filed: **June 1, 2001**

Title: **MILLING PROCESS FOR THE
PRODUCTION OF FINELY MILLED
MEDICINAL SUBSTANCES**



Art Unit: 1619

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit January 16, 2002

Signature Renee McGivern

TECHNICAL CENTER 1800/2900

FEB 25 2002

RECEIVED

REQUEST FOR CORRECTED FILING RECEIPT 1.19H

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

Please correct the Filing Receipt as follows:

1. In the Applicant section, please correct the name of Patrick Hosek to read:
PATRIK HOSEK.

2. Please correct the Atty Docket No. to read FI5028-US-CNT

A copy of the executed Declaration is enclosed as evidence of the correct spelling of Applicant. A copy of the Filing Receipt with these changes noted thereon is also enclosed.

The corrections are due to Applicant's error. The Commissioner is hereby authorized to charge the \$25.00 fee under 1.19H which is required by this paper, to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

Ronald Ort, Reg. No. 26,969
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department, EMC G-1
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

FI5028-US-CNT

#3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
AUTHELIN, ET AL.

Examiner:

Art Unit:

COPY

Serial No.: **09/871,876**

Filed: **June 1, 2001**

Title: **MILLING PROCESS FOR THE
PRODUCTION OF FINELY MILLED
MEDICINAL SUBSTANCES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

Date of Deposit January 16, 2002
Signature Renee McGinnis



Box Missing Parts
Commissioner for Patents
Washington, D.C. 20231

**LATE SUBMISSION OF DECLARATION
UNDER 37 C.F.R. 1.53(f)**

RECEIVED
FEB 25 2002
TECH CENTER 1600/2900

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE GRANTED" which was mailed on 07/31/2001 and which indicated that the oath or declaration was missing, Applicants submit herewith the Declaration for the present application and a copy of Form PTO-1533. The response was due 9/31/2001, and enclosed herewith is a Petition for a Four-month extension of time to 1/31/2002.


Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

Ronald G. Ort, Reg. No. 26,969
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

Docket No. FI5028 US CNT



COPY

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/871,876	06/01/2001	1619	710	FI5028US-ENT -NP-		16	2

005487
AVENTIS PHARMACEUTICALS, INC.
PATENTS DEPARTMENT
ROUTE 202-206, P.O. BOX 6800
BRIDGEWATER, NJ 08807-0800

COMPUTER
ENTERED

yes 8/2/01

CONFIRMATION NO. 2065
FILING RECEIPT
OC000000006365178

Date Mailed 07/31/2001

RECEIVED
B 2 5 2002
TECH CENTER 1600/2900

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jean-Rene Authelin, Saint Germain les Arpajon, FRANCE;
PATRIK Patrick Hosek, Kronberg im Taunus, GERMANY;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF PCT/GB99/04047 12/01/1999

Foreign Applications

UNITED KINGDOM 9826286.8 12/01/1998

If Required, Foreign Filing License Granted 07/31/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Milling process for the production of finely milled medicinal substances

Preliminary Class

Date: 07/31/2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/871,876	06/01/2001	Jean-Rene Authelin	FI5028US-NP

CONFIRMATION NO. 2065

FORMALITIES LETTER



005487
AVENTIS PHARMACEUTICALS, INC.
PATENTS DEPARTMENT
ROUTE 202-206, P.O. BOX 6800
BRIDGEWATER, NJ 08807-0800

Date Mailed: 07/31/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**

03/08/2002 TV0111 00000013 181982 09871876

01 FC:105 130.00 CH

*A copy of this notice **MUST** be returned with the reply.*

[Signature]
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED
FEB 25 2002
TECH CENTER 1600 2900